Merck TEA request
This article was originally published in The Rose Sheet
Executive Summary
Merck KGaA U.S. affiliate EM Industries seeks 90-day extension to convert pending citizen petition for sunscreen ingredient Eusolex 6300 into "time and extent application" for priority review. In May 21 letter to FDA, Merck counsel Buchanan Ingersoll (Washington, D.C.) says company expects to file TEA but "due to the extensive lapse of time" since petition's filing in 1980, recompiling original data "and supplementing that information with data and other relevant information generated over the last 20 years has been difficult." In April, FDA notified petitioners they have 120 days from Jan. 23 publication of "material time, material extent" rule to convert petitions into TEAs (1"The Rose Sheet" May 6, 2002, In Brief). Merck says it would consider any denial of additional time, coupled with agency's April letter, to be a "final administrative action" on the petition and would "seek relief through the judicial system"...
You may also be interested in...
Sunscreen petitions
FDA will "give priority" to reviews of time and extent applications (TEAs) submitted by firms that previously petitioned agency to include specific foreign-marketed ingredients in sunscreen monograph, FDA reiterates in six letters to ingredient suppliers and their counsel. As outlined in Jan. 23 final reg, citizen petitions must be converted to TEAs "within 120 days" of rule's publication (1"The Rose Sheet" Jan. 28, 2002, p. 9). Letters to Ciba Specialty Chemicals, EM Industries, BASF counsel and Haarmann & Reimer counsel, dated from April 19 through April 25, advise firms that agency does not "intend to take further action" on firms' respective petitions...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.